NLRP3 and lung carcinoma: Although MCC950, a potent small molecule inhibitor of NLRP3 inflammasome, was previously reported to inhibit survival, migration, and invasion in head, neck, and lung cancer [42,43], the effect of caspase-1 inhibitors, such as Ac-YVAD-cmk, on tumor growth remains controversial.